Conduct of the Collaboration. Subject to the terms and conditions of this Agreement, each Party shall use Commercially Reasonable and Diligent Efforts to conduct Research in accordance with the Research Plan and Budget, Preclinical Development in accordance with the Preclinical Plan and Budget, and the Approved Clinical Studies in accordance with the Clinical Development Plan and Budget, in each case under the supervision of the JSC. Each Party agrees to keep the JSC informed as to the progress of its activities under the Plans and Budgets.
Conduct of the Collaboration. The Parties shall cooperate to commercialize the Licensed Product in the Licensee Indications in the Territory in accordance with the terms and conditions of this Agreement.
Conduct of the Collaboration. The Parties shall cooperate to conduct Medical Affairs Activities with respect to the Product in the Field in the United States, and Commercialize the Product in the Field in the United States, in each case in accordance with the terms and conditions of this Agreement (the “US Collaboration”).
Conduct of the Collaboration. The Parties will collaborate to Manufacture, Develop, seek Regulatory Approvals for, and Commercialize the Product in the Field in their respective Licensed Territories, in each case in accordance with the terms and conditions of this Agreement (the “Collaboration”). The JCC may change the allocation of Licensed Territories at a later time based upon the Parties’ relative experience, capability and readiness to Develop, seek Regulatory Approval and/or Commercialize Product in the applicable territory; however, any such change shall require the mutual agreement of the Parties.
Conduct of the Collaboration. Subject to the terms and conditions of this Agreement, each party shall be responsible for managing and controlling its respective research obligations under the Research Plan. Each party shall proceed diligently and in a timely manner with the work set out in the Research Plan by using their respective good faith efforts to allocate sufficient time, effort, equipment and facilities to the Collaboration and to use personnel with sufficient skills and experience as are required to accomplish the Collaboration in accordance with the terms of this Agreement and Research Plan. In no event shall Metabasis be obligated to devote to the Collaboration more than the number of FTEs being funded by Merck under this Agreement. Each party shall be entitled to utilize the services of Affiliates to perform its Collaboration responsibilities. Each party shall be entitled to utilize the services of Third Parties to perform its Collaboration responsibilities only upon the prior written consent of the JRC (not to be unreasonably withheld). Notwithstanding any such use of Affiliates or Third Parties, each ***Confidential Treatment Requested party shall remain at all times responsible for the performance of its respective responsibilities under the Collaboration and shall obtain the written agreement of each such Third Party, prior to the time such Third Party initiates work, to comply with confidentiality and non use obligations equivalent to those set forth in Article 9 and to assign ownership of Inventions made in the course of Collaboration activities to such party.
Conduct of the Collaboration. 3.1 The Parties will conduct the research described in the Research Plan (attached as Exhibit A) and as described below. The JDC may amend the Research Plan at any time, but may not (i) impose on a Party an obligation that is inconsistent with this Agreement, without that Party’s consent, or (ii) amend the Research Plan in such a way that is inconsistent with Commercially Reasonable Efforts without the unanimous consent of all JDC representatives. The JDC may not amend this Agreement. Where there is a conflict between the Research Plan and this Agreement, the provisions of this Agreement will prevail.
Conduct of the Collaboration. Subject to the terms and conditions of this Agreement: (i) prior to the Amgen Option Effective Date, [***] to conduct the Research Program and the Development Program; and (ii) subsequent to the Amgen Option Effective Date, [***] to research, develop, manufacture and commercialize Compounds in the Territory in the Field in accordance with this Agreement (subject to Section [***] hereof). Amgen shall have no obligation pursuant to this Section unless and until the occurrence of the Amgen Option Effective Date.
Conduct of the Collaboration. The Parties shall cooperate to Develop the Licensed Products worldwide, conduct Medical Affairs Activities with respect to Licensed Products in the Field in the Territory, and Commercialize the Licensed Products in the Field in the Territory, in each case in accordance with the terms and conditions of this Agreement (the “Collaboration”).
Conduct of the Collaboration. The Parties shall cooperate to develop and commercialize Dmab in the Territory, in accordance with the terms and conditions of this Agreement.
Conduct of the Collaboration. 11 3.1 Objectives.....................................................................................11
